

	CLYDE PLEINARY ROOM GROUND LEVEL	HALL 2 GROUND LEVEL	HALL 3A GROUND LEVEL	HALL 3B GROUND LEVEL	LOMOND AUDITORIUM GROUND LEVEL	HALL 1 GROUND LEVEL	M1 UPPER LEVEL	FORTH ROOM GROUND LEVEL	CARRON UPPER LEVEL	RESEARCH ZONE HALL 4	THE SQUARE HALL 4	NEPHROLOGY TRAINING HUB HALL 3
08:30 09:15												
09:15 09:30	Break											
09:30 12:00												
12:00 12:15	Break											
12:15 13:15					ISS 0.1: IgA Nephropathy: Exploring Patient Impact and Advances in Disease-Specific Management [Organised and funded by Otsuka Pharmaceutical Europe Ltd. and Intended for healthcare professionals only]	ISS 0.2: Time to act: addressing kidney and cardiovascular risk in people with CKD						
13:15 13:30	Break											
13:30 16:00												
16:00 16:15	Break											
16:15 17:15												
17:15 17:30	Break											
17:30 18:30												
18:30 19:30	Welcome reception											
	Exhibition open (16:00 - 20:00)											

	CLYDE PLEINARY ROOM GROUND LEVEL	HALL 2 GROUND LEVEL	HALL 3A GROUND LEVEL	HALL 3B GROUND LEVEL	LOMOND AUDITORIUM GROUND LEVEL	HALL 1 GROUND LEVEL	M1 UPPER LEVEL	FORTH ROOM GROUND LEVEL	CARRON UPPER LEVEL	RESEARCH ZONE HALL 4	THE SQUARE HALL 4	NEPHROLOGY TRAINING HUB HALL 3
08.15 09.45												
09.45 10.00	Break										IST 1.1: Vitamin E-coated Super High-Flux Membranes: Towards Enhanced Middle Molecule Removal and Improved Biocompatibility	Renal Access catheter insertion skills (09:15 - 12:15)
10.00 11.00			ISS 1.1: Guiding Treatment Decisions in IgA Nephropathy: Bridging Evidence and Experience	ISS 1.2: Raising expectations for C3G & primary IC-MPGN management with pegcetacoplan	ISS 1.3: Kidney Health in Cardiovascular Care: Strategies for Multimodal Cardio-Renal Protection	ISS 1.4: Beyond the flare: Sustained kidney preservation starts with early intervention in lupus	ISS 1.5: Advancing Patient-Centered, Guideline-Driven Management of Hyperkalemia in Adults With CKD and Associated Comorbidities	ISS 1.6: Expanding the role of complement beyond the glomerulus - what you need to know in IgAN	ISS 1.7: Optimizing treatment of aHUS patients			
11.00 11.15	Break											
11.15 12.45												
12.45 13.00	Break											
13.00 14.00			ISS 1.8: To be or not to be—combination therapy in lupus nephritis?	ISS 1.9: The score of IgA nephropathy: impact of early diagnosis and disease drivers	ISS 1.10: Translating Evidence Into Practice: Patient-Centered, Guideline-Driven Care in ANCA-Associated Vasculitis		ISS 1.11: Towards sustainable dialysis: Every action matters	ISS 2.12: Reassessing CKD Management: A Focus on Novel Pathways and Emerging Therapies	ISS 1.13: Renal Anaemia Management in 2026: Guidelines and Clinical Insights in Dialysis Care			
14.00 14.15	Break											
14.15 14.45												
14.45 15.45												
15.45 16.00	Break										IST 1.2: Improving early CKD management through AI-based algorithms for personalized risk assessment.	PoCUS practice (14:30 - 17:30)
16.00 17.00												
17.00 17.15	Break											
17.15 18.15												
Exhibition open (9:30 - 17:30)												

	CLYDE PLEINARY ROOM GROUND LEVEL	HALL 2 GROUND LEVEL	HALL 3A GROUND LEVEL	HALL 3B GROUND LEVEL	LOMOND AUDITORIUM GROUND LEVEL	HALL 1 GROUND LEVEL	M1 UPPER LEVEL	FORTH ROOM GROUND LEVEL	CARRON UPPER LEVEL	RESEARCH ZONE HALL 4	THE SQUARE HALL 4	NEPHROLOGY TRAINING HUB HALL 3	
08.15 09.45													
09.45 10.00	Break										IST 2.1: Nephropathic Cystinosis in Focus: Supporting Transition and Transplantation in Nephrology Care	Renal Access catheter insertion skills (09:15 - 12:15)	
10.00 11.00						ISS 2.1: CKD-associated Pruritus Interactive Decision Forum	ISS 2.2: Leading the Shift in CKD Anemia Care: Spotlight on HIF-PHIs	ISS 2.3: New Perspectives on Podocytopathies: Glomerular Injury, Practical Insights and Emerging Treatment Approaches					
11.00 11.15	Break										IST 2.2: Steady concentration peritoneal dialysis increases ultrafiltration and sodium removal: a step change in volume management		
11.15 12.45													
12.45 13.00	Break										IST 2.3: Nephropathic Cystinosis in Focus: Supporting Transition and Transplantation in Nephrology Care		
13.00 14.00			ISS 2.9: Emerging Therapeutic Approaches in IgA Nephropathy: Innovations in B-Cell Modulation and Dual BAFF/APRIL Inhibition	SS 2.10: Evolving Clinical Practice in C3 Glomerulopathy (C3G): From Unmet Needs to Real-Life Experiences	ISS 2.11: Reframing IgAN Care: Patient-Centered Strategies to Curb Proteinuria and Preserve Kidney Function	ISS 2.12: Reassessing CKD Management: A Focus on Cardiorenal Pathways and Emerging Therapies	ISS 2.13: Harnessing the Power of UACR to Shape the Future of CKD Management	ISS 2.14: Fabry disease: from molecular understanding to clinical outcomes	ISS 2.15: Shifting Perspectives in aHUS				
14.00 14.15	Break												
14.15 14.45													
14.45 15.45													
15.45 16.00	Break												
16.00 17.00												PoCUS practice (14:30 - 17:30)	
17.00 17.15	Break												
17.15 18.15													
Exhibition open (9:30 - 17:30)													